Template:Pyelonephritis antibiotics: Difference between revisions

No edit summary
No edit summary
Line 5: Line 5:
*[[Cefpodoxime]] 200 mg BID x10-14 days OR<ref>Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.</ref>
*[[Cefpodoxime]] 200 mg BID x10-14 days OR<ref>Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.</ref>
*[[Levofloxacin]] 750mg PO once x 7 days<ref>Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.</ref>
*[[Levofloxacin]] 750mg PO once x 7 days<ref>Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.</ref>
====Inpatient Options====
====Adult Inpatient Options====
*[[Ciprofloxacin]] 400mg IV q12hr OR
*[[Ciprofloxacin]] 400mg IV q12hr OR
*[[Ceftriaxone]] 1gm IV QD OR
*[[Ceftriaxone]] 1gm IV QD OR
Line 13: Line 13:
*[[Cefepime]] 2gm IV q8hr OR
*[[Cefepime]] 2gm IV q8hr OR
*[[Imipenem]] 500mg IV q8hr
*[[Imipenem]] 500mg IV q8hr
====Pediatric Inpatient Options====
*[[Ceftriaxone]] 75mg/kg IV once daily
*[[Cefotaxime]] 50mg/kg IV q8hrs
*[[Ampicillin]] 25mg/kg IV q6hrs + [[Gentamicin]] 2.5mg/kg IV q8hrs

Revision as of 16:16, 20 April 2015

Treatment is targeted at E. coli, Enterococcus, Klebsiella, Proteus, S. saprophyticus

Outpatient

Consider one dose of Ceftriaxone 1g IV or Gentamycin 7mg/kg IV if the regional susceptibility of TMP/SMX or Fluoroquinolones is <80%

Adult Inpatient Options

Pediatric Inpatient Options

  1. Colgan R, Williams M. Diagnosis and treatment of acute uncomplicated cystitis. Am Fam Physician. 2011 Oct 1;84(7):771-6.
  2. Sandberg T. et al. Ciprofloxacin for 7 days versus 14 days in women with acute pyelonephritis: a randomised, open-label and double-blind, placebo-controlled, non-inferiority trial. Lancet. 2012 Aug 4;380(9840):484-90.